<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135042</url>
  </required_header>
  <id_info>
    <org_study_id>NRG-HN001</org_study_id>
    <secondary_id>NCI-2014-00635</secondary_id>
    <secondary_id>RTOG-1305</secondary_id>
    <secondary_id>NRG-HN001</secondary_id>
    <secondary_id>NRG-HN001</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <secondary_id>U10CA021661</secondary_id>
    <nct_id>NCT02135042</nct_id>
    <nct_alias>NCT02179164</nct_alias>
  </id_info>
  <brief_title>Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA</brief_title>
  <official_title>Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NRG Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are two study questions we are asking in this randomized phase II/III trial based on a
      blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally
      advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard
      concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if
      there is no detectable EBV DNA in their plasma, then patients are randomized to either
      standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still
      detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and
      fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high
      energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin,
      fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
      stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil
      is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in
      treating patients with nasopharyngeal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether substituting adjuvant concurrent high dose cisplatin (CDDP) and
      fluorouracil (5-FU) with gemcitabine (gemcitabine hydrochloride) and paclitaxel will result
      in superior progression-free survival. (Detectable Plasma Epstein Barr Virus [EBV]
      Deoxyribonucleic Acid [DNA] Cohort randomized Phase II) II. To determine whether omitting
      adjuvant CDDP and 5-FU (observation alone in the adjuvant setting) will result in
      non-inferior overall survival as compared with those patients receiving adjuvant CDDP and
      5-FU chemotherapy. (Undetectable Plasma EBV DNA Cohort Phase III)

      SECONDARY OBJECTIVES:

      I. Time to distant metastasis. (Randomized Phase II and Phase III) II. Time to local
      progression. (Randomized Phase II and Phase III) III. Time to regional progression.
      (Randomized Phase II and Phase III) IV. Progression-free survival (Undetectable Cohort). V.
      Overall survival (Detectable Cohort). VI. Acute and late toxicity profiles based on
      clinician-reported Common Terminology Criteria for Adverse Events (CTCAE), version (v.) 4.
      (Randomized Phase II and Phase III) VII. Death during or within 30 days of end of protocol
      treatment. (Randomized Phase II and Phase III) VIII. Quality of life (general and physical
      well-being). (Randomized Phase II and Phase III) IX. Quality of life (hearing). (Randomized
      Phase II and Phase III) X. Quality of life (peripheral neuropathy). (Randomized Phase II and
      Phase III) XI. Cost effectiveness. (Randomized Phase II and Phase III)

      OUTLINE:

      Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) 5 days a week
      for 6.5 weeks and receive low-dose cisplatin intravenously (IV) over 30-60 minutes once
      weekly during IMRT. Beginning 1 week after chemoradiation, plasma samples are collected for
      EBV DNA analysis.

      PHASE II: Patients with detectable EBV DNA from pre-treatment analysis are randomized to 1 of
      2 treatment arms.

      ARM I: Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and
      fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of
      IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or
      unacceptable toxicity.

      ARM II: Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine
      hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT.
      Treatment repeats every 21 days for 4 courses in the absence of disease progression or
      unacceptable toxicity.

      PHASE III:

      Patients with undetectable EBV DNA from pre-treatment analysis are randomized to 1 of 2
      treatment arms.

      ARM III: Patients receive PF regimen as in Arm I.

      ARM IV: Patients undergo clinical observation.

      After completion of study treatment, patients are followed up every 4 months for 2 years,
      every 6 months for 3 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS) (Undetectable Plasma EBV DNA Cohort Phase III)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided log rank test. The confidence interval approach will be used for the final analysis of OS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (Detectable Plasma EBV DNA Cohort Phase II)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided log rank test. A one-sided log rank test will be used to compare the PFS at a significance level of 0.1379.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in pure tone audiometry (Phase II and III)</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>Correlation between categorical measures will be summarized by odds ratios, chi-square tests, and associated measures. Adjusted correlation may be derived from analysis of covariance (ANCOVA) models or derived directly using nonparametric analysis of variance (ANOVA) models if normality assumption is violated. Correlations between HHIE-S PRO scores and PTA and FACT-NP hearing, and PTA will be compared as dependent statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in QOL (hearing) as assessed by the Hearing Handicap Inventory for the Elderly-Screening version (HHIE-S) (Phase II and III)</measure>
    <time_frame>Baseline to up to 24 months</time_frame>
    <description>QOL analysis including overall score and change from baseline will be summarized using mean and standard deviation at each time point for each arm. Overall and nasopharyngeal-specific QOL, hearing QOL (FACT-NP hearing domain, HHIE-S scores), peripheral neuropathy QOL over the short and long term and pure-tone audiometry (PTA) scores will be compared using a two sample independent t test and paired t test if the comparison is within the experimental arm between different time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in QOL (peripheral neuropathy) as assessed by the FACT-Taxane (Phase II and III)</measure>
    <time_frame>Baseline to up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life (QOL) (general and physical well-being) assessed using the Functional Assessment of Cancer Therapy (FACT)-Nasopharyngeal (NP) (Phase II and III)</measure>
    <time_frame>Baseline to up to 24 months</time_frame>
    <description>Changes in patient reported outcome (PRO) scores will be correlated to clearance or non-clearance of EBV titers. Descriptive statistics derived from FACT-NP will be used to enrich the understanding of QOL as it pertains to the 2 phase III arms of observation versus additional adjuvant chemotherapy. Univariable and multivariable analysis will be performed using the Cox proportional hazards model for OS and distant metastasis. Pearson correlation will be estimated between general and physical well-being. QOL measures and change from baseline will be correlated to EBV DNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness as assessed by the health-related QOL (HRQOL) from the EuroQol (EQ-5D) instrument (Phase II and III)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Incremental cost effectiveness ratios will be compared to determine the probability of cost effectiveness of various interventions, with sensitivity analyses to identify model weaknesses. The expected value of perfect information will be determined to delimit the upper boundary for cost-effective future investment in this area of research.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute grade 3-5 adverse events (Phase II and III)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Rates of specific acute toxicity profiles and late toxicity profiles will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death (Phase II and III)</measure>
    <time_frame>Up to 30 days of end of protocol treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of late grade 3-5 adverse events (Phase II and III)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Rates of specific acute toxicity profiles and late toxicity profiles will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Detectable Plasma EBV DNA Cohort Phase II)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Undetectable Plasma EBV DNA Cohort Phase III)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant metastasis (DM) (Phase II and III)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local progression (Phase II and III)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to regional progression (Phase II and III)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Defined as an estimated increase in the size of the tumor (product of the perpendicular diameters of the two largest dimensions) of greater than 25%, taking as reference the smallest value of all previous measurements or appearance of new areas of malignant disease. The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">924</enrollment>
  <condition>Epstein-Barr Virus Infection</condition>
  <condition>Stage II Nasopharyngeal Carcinoma</condition>
  <condition>Stage III Nasopharyngeal Carcinoma</condition>
  <condition>Stage IVA Nasopharyngeal Carcinoma</condition>
  <condition>Stage IVB Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive PF regimen as in Arm I of Phase II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (chemoradiation, observation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo clinical observation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)</arm_group_label>
    <arm_group_label>Arm III (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, observation)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Observation</intervention_name>
    <description>Undergo clinical observation</description>
    <arm_group_label>Arm IV (chemoradiation, observation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm III (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Actino-Hermal</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Arumel</other_name>
    <other_name>Cytosafe</other_name>
    <other_name>Efudex</other_name>
    <other_name>Efurix</other_name>
    <other_name>Fiverocil</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluoroplex</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Flurox</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
    <other_name>Timazin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm I (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)</arm_group_label>
    <arm_group_label>Arm III (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, observation)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)</arm_group_label>
    <arm_group_label>Arm III (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, observation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)</arm_group_label>
    <arm_group_label>Arm III (chemoradiation, cisplatin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm IV (chemoradiation, observation)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the
             nasopharynx

          -  Patients must have detectable pretreatment plasma EBV DNA, determined by the central
             lab prior to Step 2 registration

          -  Stage II-IVB disease (American Joint Committee on Cancer [AJCC], 7th edition [ed.])
             with no evidence of distant metastasis, based upon the following minimum diagnostic
             workup:

               -  History/physical examination by a Medical Oncologist or Clinical Oncologist or
                  Radiation Oncologist or Ear, Nose, Throat specialist (ENT), which must include an
                  endoscopic evaluation, a complete list of current medications, and assessment of
                  weight and weight loss in the past 6 months within 21 days prior to registration

               -  Evaluation of tumor extent with magnetic resonance imaging (MRI) of the
                  nasopharynx and neck within 28 days prior to registration; if MRI is medically
                  contraindicated, obtain computed tomography (CT) scan with =&lt; 3 mm contiguous
                  slices with contrast and bone windows (to evaluate base of skull involvement);
                  Note: If a treatment planning CT scan is used, it must be with =&lt; 3 mm contiguous
                  slices with contrast and be read by a radiologist

               -  To rule out distant metastasis, patients must undergo the following imaging
                  within 28 days prior to registration:

                    -  A CT scan with contrast of the chest, abdomen, and/or pelvis or a total body
                       positron emission tomography (PET)/CT scan (non-contrast PET/CT is
                       acceptable)

                    -  A bone scan only when there is suspicion of bone metastases (a PET/CT scan
                       can substitute for the bone scan)

          -  Zubrod performance status 0-1 within 21 days prior to registration

          -  Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm^3

          -  Platelets &gt;= 100,000 cells/mm^3

          -  Hemoglobin &gt;= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] &gt;= 8.0 g/dl is acceptable)

          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =&lt; 1.5 x
             institutional ULN

          -  Alkaline phosphatase =&lt; 1.5 x institutional ULN

          -  Serum creatinine =&lt; 1.5 mg/dl or calculated creatinine clearance (CC) &gt;= 50 ml/min
             determined by 24-hour urine collection or estimated by Cockcroft-Gault formula

          -  Negative serum pregnancy test within 14 days prior to registration for women of
             childbearing potential

          -  Women of childbearing potential and male participants who are sexually active must
             agree to use a medically effective means of birth control throughout protocol
             treatment

          -  Patient must provide study specific informed consent prior to study entry, including
             the mandatory pre-treatment plasma EBV DNA assay

        Exclusion Criteria:

          -  Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless
             disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of
             the breast, oral cavity, or cervix are all permissible)

          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
             different cancer is allowable; however, at least 6-weeks recovery is necessary if the
             last regimen included nitrosourea or mitomycin

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Patients with hearing loss assessed to be primarily sensorineural in nature, requiring
             a hearing aid, or intervention (i.e. interfering in a clinically significant way with
             activities of daily living); a conductive hearing loss from tumor-related otitis media
             is allowed

          -  &gt;= Grade 2 peripheral sensory neuropathy (CTCAE, v. 4.0)

          -  Severe, active co-morbidity, defined as follows:

               -  Major medical or psychiatric illness, which in the investigator's opinion would
                  interfere with the completion of therapy and follow up or with full understanding
                  of the risks and potential complications of the therapy

               -  Unstable angina and/or uncontrolled congestive heart failure

               -  Myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration; note that patients switched from IV antibiotics and currently on
                  oral antibiotics whose infection is assessed to be adequately treated or
                  controlled are eligible

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 days prior to
                  registration

               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
                  Control and Prevention (CDC) definition; note, however, that human
                  immunodeficiency virus (HIV) testing is not required for entry into this protocol

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception

          -  Prior allergic reaction to the study drug(s) involved in this protocol

          -  Patients with undetectable pre-treatment plasma EBV DNA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon A. Spencer</last_name>
      <phone>205-934-0220</phone>
      <email>tmyrick@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon A. Spencer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Kirklin Clinic at Acton Road</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Medical Center-University Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Centers Radiation Oncology Services-Auburn</name>
      <address>
        <city>Auburn</city>
        <state>California</state>
        <zip>95603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center-Herrick Campus</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mills-Peninsula Medical Center</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Centers Radiation Oncology Services-Cameron Park</name>
      <address>
        <city>Cameron Park</city>
        <state>California</state>
        <zip>95682</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nayana L. Vora</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Nayana L. Vora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fresno Cancer Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland-Broadway</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Ejadi</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Ejadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation Health Care</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quynh-Thu X. Le</last_name>
      <phone>650-498-7061</phone>
      <email>ccto-office@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Quynh-Thu X. Le</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Rancho Cordova Cancer Center</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rohnert Park Cancer Center</name>
      <address>
        <city>Rohnert Park</city>
        <state>California</state>
        <zip>94928</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Centers Radiation Oncology Services-Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Permanente Medical Group-Roseville Radiation Oncology</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95678</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Sacramento Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center-Pacific Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue S. Yom</last_name>
      <phone>877-827-3222</phone>
    </contact>
    <investigator>
      <last_name>Sue S. Yom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nayana L. Vora</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Nayana L. Vora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Cancer Treatment Center</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha A. Seaward</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Samantha A. Seaward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation-Sunnyvale</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Centers Radiation Oncology Services-Vacaville</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95687</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher U. Jones</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Colorado Medical Center</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Sturtz</last_name>
      <phone>303-777-2663</phone>
      <email>ccrp@co-cancerresearch.org</email>
    </contact>
    <investigator>
      <last_name>Keren Sturtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McKee Medical Center</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Sturtz</last_name>
      <phone>303-777-2663</phone>
      <email>ccrp@co-cancerresearch.org</email>
    </contact>
    <investigator>
      <last_name>Keren Sturtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parker Adventist Hospital</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>SCL Health Lutheran Medical Center</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Sturtz</last_name>
      <phone>303-777-2663</phone>
      <email>ccrp@co-cancerresearch.org</email>
    </contact>
    <investigator>
      <last_name>Keren Sturtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zain A. Husain</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Zain A. Husain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan J. Beitler</last_name>
      <phone>888-946-7447</phone>
    </contact>
    <investigator>
      <last_name>Jonathan J. Beitler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan J. Beitler</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Jonathan J. Beitler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan J. Beitler</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan J. Beitler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cancer Center of Hawaii-Pali Momi</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth N. Sumida</last_name>
      <phone>808-678-9000</phone>
    </contact>
    <investigator>
      <last_name>Kenneth N. Sumida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth N. Sumida</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth N. Sumida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cancer Center of Hawaii-Liliha</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth N. Sumida</last_name>
      <phone>808-547-6881</phone>
    </contact>
    <investigator>
      <last_name>Kenneth N. Sumida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Cancer Care Center-Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bharat B. Mittal</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Bharat B. Mittal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John H Stroger Jr Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas E. Lad</last_name>
      <phone>312-864-5204</phone>
    </contact>
    <investigator>
      <last_name>Thomas E. Lad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists of Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan A. Faller</last_name>
      <phone>217-876-4740</phone>
      <email>rhamrick@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan A. Faller</last_name>
      <phone>217-876-4740</phone>
      <email>rhamrick@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crossroads Cancer Center</name>
      <address>
        <city>Effingham</city>
        <state>Illinois</state>
        <zip>62401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan A. Faller</last_name>
      <phone>217-876-4740</phone>
      <email>rhamrick@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan A. Faller</last_name>
      <phone>217-788-3528</phone>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalika P. Sarma</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Kalika P. Sarma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A. Hornback</last_name>
      <phone>800-284-7370</phone>
    </contact>
    <investigator>
      <last_name>David A. Hornback</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Behrens</last_name>
      <phone>515-241-6727</phone>
    </contact>
    <investigator>
      <last_name>Robert J. Behrens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaker R. Dakhil</last_name>
      <phone>800-362-0070</phone>
      <email>Keisha.humphries@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Shaker R. Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaker R. Dakhil</last_name>
      <phone>316-268-5374</phone>
      <email>Keisha.humphries@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Shaker R. Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Tang</last_name>
      <phone>443-849-3706</phone>
    </contact>
    <investigator>
      <last_name>Mei Tang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ranee Mehra</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ranee Mehra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert E. Martell</last_name>
      <phone>617-636-5000</phone>
      <email>ContactUsCancerCenter@TuftsMedicalCenter.org</email>
    </contact>
    <investigator>
      <last_name>Robert E. Martell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie W. Chan</last_name>
      <phone>877-726-5130</phone>
    </contact>
    <investigator>
      <last_name>Annie W. Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minh T. Truong</last_name>
      <phone>617-638-8265</phone>
    </contact>
    <investigator>
      <last_name>Minh T. Truong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis P. Worden</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Francis P. Worden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute?Downriver</name>
      <address>
        <city>Brownstown</city>
        <state>Michigan</state>
        <zip>48183</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Macomb Hospital-Clinton Township</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>313-916-1784</phone>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>313-916-1784</phone>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Narayan</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford West Bloomfield Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor M. Walker</last_name>
      <phone>888-734-5322</phone>
    </contact>
    <investigator>
      <last_name>Eleanor M. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Foote</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Robert L. Foote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Cape Girardeau</city>
        <state>Missouri</state>
        <zip>63703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan A. Faller</last_name>
      <phone>573-334-2230</phone>
      <email>sfmc@sfmc.net</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas R. Adkins</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas R. Adkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delbert Day Cancer Institute at PCRMC</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>573-458-7504</phone>
      <email>jrichards@research.pcrmc.com</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas R. Adkins</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas R. Adkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas R. Adkins</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas R. Adkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>314-251-6770</phone>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Saint Peters Hospital</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas R. Adkins</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas R. Adkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>417-269-4520</phone>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tien-Shew W. Huang</last_name>
      <phone>402-354-5144</phone>
    </contact>
    <investigator>
      <last_name>Tien-Shew W. Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Ellerton</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>John A. Ellerton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Ellerton</last_name>
      <phone>412-339-5294</phone>
      <email>Roster@nrgoncology.org</email>
    </contact>
    <investigator>
      <last_name>John A. Ellerton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Y. Lee</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Nancy Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Y. Lee</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Nancy Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhur K. Garg</last_name>
      <phone>718-379-6862</phone>
      <email>sforde@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Madhur K. Garg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Brooklyn Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishnamurthi Sundaram</last_name>
      <phone>718-780-3677</phone>
      <email>Adg9003@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Krishnamurthi Sundaram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Y. Lee</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Nancy Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Y. Lee</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Nancy Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth S. Hu</last_name>
      <phone>212-263-4434</phone>
      <email>prmc.coordinator@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth S. Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Y. Lee</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Nancy Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Yuhchyau Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Y. Lee</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Nancy Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Sleepy Hollow</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Akron General</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Geauga Hospital</name>
      <address>
        <city>Chardon</city>
        <state>Ohio</state>
        <zip>44024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yao</last_name>
      <phone>800-641-2422</phone>
      <email>CTUReferral@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Min Yao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati/Barrett Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin P. Redmond</last_name>
      <phone>513-558-4553</phone>
      <email>uchealthnews@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin P. Redmond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yao</last_name>
      <phone>800-641-2422</phone>
      <email>CTUReferral@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Min Yao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center/Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Adelstein</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>David J. Adelstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Adelstein</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>David J. Adelstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dukagjin M. Blakaj</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Dukagjin M. Blakaj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center-Elyria</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yao</last_name>
      <phone>800-641-2422</phone>
      <email>CTUReferral@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Min Yao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center Mansfield</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Adelstein</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>David J. Adelstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Care</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Adelstein</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>David J. Adelstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center Strongsville</name>
      <address>
        <city>Strongsville</city>
        <state>Ohio</state>
        <zip>44136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Adelstein</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>David J. Adelstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flower Hospital</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhijit B. Saste</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Abhijit B. Saste</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pointe</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin P. Redmond</last_name>
      <email>clinicaltrials@ucphysicians.com</email>
    </contact>
    <investigator>
      <last_name>Kevin P. Redmond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Wooster Family Health and Surgery Center</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Adelstein</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>David J. Adelstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. S. Thompson</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>J. S. Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>405-752-3402</phone>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital and Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Y. Kee</last_name>
      <phone>800-220-4937</phone>
      <email>cancer@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Y. Kee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Concord Health Center</name>
      <address>
        <city>Chadds Ford</city>
        <state>Pennsylvania</state>
        <zip>19317</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence P. Cescon</last_name>
      <phone>610-988-9323</phone>
    </contact>
    <investigator>
      <last_name>Terrence P. Cescon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert D. Siegel</last_name>
      <phone>864-603-6213</phone>
      <email>meissa_beckman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert D. Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center-Pelham</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C. Griffin</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Patricia C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Seneca</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C. Griffin</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Patricia C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
      <email>kwilliams8@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Sher</last_name>
      <phone>214-648-7097</phone>
    </contact>
    <investigator>
      <last_name>David J. Sher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Fork Hospital / Huntsman Intermountain Cancer Center</name>
      <address>
        <city>American Fork</city>
        <state>Utah</state>
        <zip>84003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilija N. Avizonis</last_name>
      <phone>801-855-4100</phone>
      <email>officeofresearch@imail.org</email>
    </contact>
    <investigator>
      <last_name>Vilija N. Avizonis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilija N. Avizonis</last_name>
      <phone>801-507-3950</phone>
      <email>officeofresearch@imail.org</email>
    </contact>
    <investigator>
      <last_name>Vilija N. Avizonis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverton Hospital</name>
      <address>
        <city>Riverton</city>
        <state>Utah</state>
        <zip>84065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilija N. Avizonis</last_name>
      <phone>801-507-3950</phone>
      <email>officeofresearch@imail.org</email>
    </contact>
    <investigator>
      <last_name>Vilija N. Avizonis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dixie Medical Center Regional Cancer Center</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilija N. Avizonis</last_name>
      <phone>435-688-4167</phone>
      <email>officeofresearch@imail.org</email>
    </contact>
    <investigator>
      <last_name>Vilija N. Avizonis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists-Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilija N. Avizonis</last_name>
      <phone>801-933-6070</phone>
      <email>officeofresearch@imail.org</email>
    </contact>
    <investigator>
      <last_name>Vilija N. Avizonis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collin D. Driscoll</last_name>
      <phone>608-775-2385</phone>
      <email>cancerctr@gundersenhealth.org</email>
    </contact>
    <investigator>
      <last_name>Collin D. Driscoll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul M. Harari</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <investigator>
      <last_name>Paul M. Harari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Medical Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Husak</last_name>
      <phone>800-782-8581</phone>
      <email>oncology.clinical.trials@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Michael Husak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic-Minocqua Center</name>
      <address>
        <city>Minocqua</city>
        <state>Wisconsin</state>
        <zip>54548</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Husak</last_name>
      <phone>800-782-8581</phone>
      <email>oncology.clinical.trials@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Michael Husak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic-Rice Lake Center</name>
      <address>
        <city>Rice Lake</city>
        <state>Wisconsin</state>
        <zip>54868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Husak</last_name>
      <phone>800-782-8581</phone>
      <email>oncology.clinical.trials@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Michael Husak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Hospital</name>
      <address>
        <city>Stevens Point</city>
        <state>Wisconsin</state>
        <zip>54481</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Treatment Center</name>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <zip>54476</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Husak</last_name>
      <phone>888-799-3989</phone>
      <email>oncology.clinical.trials@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Michael Husak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil S. Chua</last_name>
      <phone>403-521-3433</phone>
    </contact>
    <investigator>
      <last_name>Neil S. Chua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil S. Chua</last_name>
      <phone>780-432-8500</phone>
    </contact>
    <investigator>
      <last_name>Neil S. Chua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John (Joon-Hyung) Kim</last_name>
      <phone>416-946-4501</phone>
      <email>clinical.trials@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>John (Joon-Hyung) Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Department of Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Shenouda</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>42953</phone_ext>
      <email>evelyn.ortega@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>George Shenouda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Shenouda</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>48354</phone_ext>
      <email>evelyn.ortega@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>George Shenouda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Chinese University of Hong Kong-Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony T. Chan</last_name>
      <email>ccrb@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Anthony T. Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Guangdong Province</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaosu Hu</last_name>
      <phone>(8621) 64175590 X 81112</phone>
    </contact>
    <investigator>
      <last_name>Chaosu Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry C. Sze</last_name>
      <phone>011 852 2595 7920</phone>
    </contact>
    <investigator>
      <last_name>Henry C. Sze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoke L. Soong</last_name>
      <phone>65 6225 5655</phone>
      <email>cancerhelpline@nccs.com.sg</email>
    </contact>
    <investigator>
      <last_name>Yoke L. Soong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Hospital-Lin Kou Medical Center</name>
      <address>
        <city>Taoyuan</city>
        <zip>33333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

